This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The eye melanoma market size has grown strongly in recent years. It will grow from $9.1 billion in 2024 to $9.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased awareness and early detection, aging population and sun exposure, rise in skin cancer incidence, development of targeted therapies, patient advocacy and support programs.
The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $13.77 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to continued public health initiatives, research in genetic and molecular profiling, global aging population trends. Major trends in the forecast period include integration of artificial intelligence (ai), emergence of targeted therapies, focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging, advancements in treatment modalities, technological innovations in imaging.
The projected rise in eye cancer cases is poised to be a significant driver for the eye melanoma market's expansion in the coming years. Eye cancer denotes the abnormal and uncontrolled growth of cells within the eye's structures. Enhanced detection techniques, increased awareness, and advancements in treatment options have led to a heightened demand for specialized therapies and interventions to effectively manage early cases. For example, according to the American Cancer Society's January 2023 report, eye and orbital cancer cases increased to 3,490 in 2023, marking a 5.12% growth from 3,320 in 2021. Therefore, the surge in eye cancer cases is expected to fuel the growth of the eye melanoma market.
The anticipated growth in the geriatric population is set to boost the eye melanoma market's expansion in the foreseeable future. Eye melanoma, a form of eye cancer, tends to become more prevalent with age due to prolonged exposure to environmental factors and genetic predispositions among older individuals. The expanding population of older adults increases the potential number of individuals susceptible to eye melanoma. As reported by the World Health Organization in October 2022, the population aged 60 and above surged from 1 billion in 2021 to 1.4 billion in 2022, with projections to double to 2.1 billion by 2050. Hence, the growing geriatric population is expected to drive the growth of the eye melanoma market.
Companies at the forefront of the eye melanoma treatment sector are dedicated to pioneering innovative and specialized treatments, particularly immunotherapies and targeted therapies, aiming to elevate patient outcomes and improve their quality of life. These novel treatment modalities have recently made significant strides in the field of oncology. For example, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical firm specializing in soluble T-cell receptor technology for biological drug development, obtained approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn). This groundbreaking therapy, the first of its kind for individuals with unresectable or metastatic uveal melanoma (mUM), operates as an immunotherapy targeting the gp100 protein found on the surface of uveal melanoma cells. By activating the patient's immune system through engineered T-cell receptors, Kimmtrak enables a precision-focused approach to eliminating melanoma, leveraging specialized immune cells for cancer treatment.
In January 2023, Health Network One, a leading US-based specialty benefit management company, acquired Premier Eye Care for an undisclosed amount. This acquisition enables Health Network One to broaden its provider network, improve clinical quality, and foster innovation in ophthalmology services. Premier Eye Care, a US-based company, specializes in diagnosing and treating eye melanoma through various methods such as surgery, radiation, and laser therapy.
Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc, Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd., IDEAYA Biosciences, Immunocore Limited, Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.
North America was the largest region in the eye melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eye melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The eye melanoma market consists of revenues earned by entities by providing fine needle aspiration (FNA) techniques, blood testing, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The eye melanoma market also includes sales of drugs and therapeutics such as chemotherapy, cryotherapy, and photodynamic therapy (PDT). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Eye melanoma is a form of cancer that develops in the melanocytes, the cells responsible for producing melanin within the eye. This cancer can manifest in different parts of the eye, including the uvea, iris, and choroid. Eye melanoma stands as the most common primary intraocular cancer in adults and may lead to vision issues, alterations in eye color, and other symptoms, depending on its location and size.
The primary types of eye melanoma are found in the uvea, sclera, and retina. The uvea constitutes the middle layer of the eye, encompassing the iris, ciliary body, and choroid, housing blood vessels that supply nutrients to the eye. Various forms of radiation therapy, such as plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery, are employed to target and reduce the size of uveal melanomas. Diagnosis involves imaging, biopsy, and eye examinations, while treatments include surgery, radiation therapy, targeted therapy, immunotherapy, and other approaches. These treatments are typically administered by end users such as hospitals, clinics, and academic institutes.
The eye melanoma market research report is one of a series of new reports that provides eye melanoma market statistics, including eye melanoma industry global market size, regional shares, competitors with an eye melanoma market share, detailed eye melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the eye melanoma industry. This eye melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The eye melanoma market size has grown strongly in recent years. It will grow from $9.1 billion in 2024 to $9.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased awareness and early detection, aging population and sun exposure, rise in skin cancer incidence, development of targeted therapies, patient advocacy and support programs.
The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $13.77 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to continued public health initiatives, research in genetic and molecular profiling, global aging population trends. Major trends in the forecast period include integration of artificial intelligence (ai), emergence of targeted therapies, focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging, advancements in treatment modalities, technological innovations in imaging.
The projected rise in eye cancer cases is poised to be a significant driver for the eye melanoma market's expansion in the coming years. Eye cancer denotes the abnormal and uncontrolled growth of cells within the eye's structures. Enhanced detection techniques, increased awareness, and advancements in treatment options have led to a heightened demand for specialized therapies and interventions to effectively manage early cases. For example, according to the American Cancer Society's January 2023 report, eye and orbital cancer cases increased to 3,490 in 2023, marking a 5.12% growth from 3,320 in 2021. Therefore, the surge in eye cancer cases is expected to fuel the growth of the eye melanoma market.
The anticipated growth in the geriatric population is set to boost the eye melanoma market's expansion in the foreseeable future. Eye melanoma, a form of eye cancer, tends to become more prevalent with age due to prolonged exposure to environmental factors and genetic predispositions among older individuals. The expanding population of older adults increases the potential number of individuals susceptible to eye melanoma. As reported by the World Health Organization in October 2022, the population aged 60 and above surged from 1 billion in 2021 to 1.4 billion in 2022, with projections to double to 2.1 billion by 2050. Hence, the growing geriatric population is expected to drive the growth of the eye melanoma market.
Companies at the forefront of the eye melanoma treatment sector are dedicated to pioneering innovative and specialized treatments, particularly immunotherapies and targeted therapies, aiming to elevate patient outcomes and improve their quality of life. These novel treatment modalities have recently made significant strides in the field of oncology. For example, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical firm specializing in soluble T-cell receptor technology for biological drug development, obtained approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn). This groundbreaking therapy, the first of its kind for individuals with unresectable or metastatic uveal melanoma (mUM), operates as an immunotherapy targeting the gp100 protein found on the surface of uveal melanoma cells. By activating the patient's immune system through engineered T-cell receptors, Kimmtrak enables a precision-focused approach to eliminating melanoma, leveraging specialized immune cells for cancer treatment.
In January 2023, Health Network One, a leading US-based specialty benefit management company, acquired Premier Eye Care for an undisclosed amount. This acquisition enables Health Network One to broaden its provider network, improve clinical quality, and foster innovation in ophthalmology services. Premier Eye Care, a US-based company, specializes in diagnosing and treating eye melanoma through various methods such as surgery, radiation, and laser therapy.
Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc, Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd., IDEAYA Biosciences, Immunocore Limited, Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.
North America was the largest region in the eye melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eye melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The eye melanoma market consists of revenues earned by entities by providing fine needle aspiration (FNA) techniques, blood testing, and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The eye melanoma market also includes sales of drugs and therapeutics such as chemotherapy, cryotherapy, and photodynamic therapy (PDT). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Eye melanoma is a form of cancer that develops in the melanocytes, the cells responsible for producing melanin within the eye. This cancer can manifest in different parts of the eye, including the uvea, iris, and choroid. Eye melanoma stands as the most common primary intraocular cancer in adults and may lead to vision issues, alterations in eye color, and other symptoms, depending on its location and size.
The primary types of eye melanoma are found in the uvea, sclera, and retina. The uvea constitutes the middle layer of the eye, encompassing the iris, ciliary body, and choroid, housing blood vessels that supply nutrients to the eye. Various forms of radiation therapy, such as plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery, are employed to target and reduce the size of uveal melanomas. Diagnosis involves imaging, biopsy, and eye examinations, while treatments include surgery, radiation therapy, targeted therapy, immunotherapy, and other approaches. These treatments are typically administered by end users such as hospitals, clinics, and academic institutes.
The eye melanoma market research report is one of a series of new reports that provides eye melanoma market statistics, including eye melanoma industry global market size, regional shares, competitors with an eye melanoma market share, detailed eye melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the eye melanoma industry. This eye melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Eye Melanoma Market Characteristics3. Eye Melanoma Market Trends and Strategies4. Eye Melanoma Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Eye Melanoma Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Eye Melanoma Market34. Recent Developments in the Eye Melanoma Market
5. Global Eye Melanoma Growth Analysis and Strategic Analysis Framework
6. Eye Melanoma Market Segmentation
7. Eye Melanoma Market Regional and Country Analysis
8. Asia-Pacific Eye Melanoma Market
9. China Eye Melanoma Market
10. India Eye Melanoma Market
11. Japan Eye Melanoma Market
12. Australia Eye Melanoma Market
13. Indonesia Eye Melanoma Market
14. South Korea Eye Melanoma Market
15. Western Europe Eye Melanoma Market
16. UK Eye Melanoma Market
17. Germany Eye Melanoma Market
18. France Eye Melanoma Market
19. Italy Eye Melanoma Market
20. Spain Eye Melanoma Market
21. Eastern Europe Eye Melanoma Market
22. Russia Eye Melanoma Market
23. North America Eye Melanoma Market
24. USA Eye Melanoma Market
25. Canada Eye Melanoma Market
26. South America Eye Melanoma Market
27. Brazil Eye Melanoma Market
28. Middle East Eye Melanoma Market
29. Africa Eye Melanoma Market
30. Eye Melanoma Market Competitive Landscape and Company Profiles
31. Eye Melanoma Market Other Major and Innovative Companies
35. Eye Melanoma Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Eye Melanoma Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on eye melanoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for eye melanoma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The eye melanoma market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Site: Uvea; Sclera; Retina2) By Diagnosis: Imaging; Biopsy; Eye Exam
3) By Treatment: Surgery; Radiation Therapy; Targeted Therapy; Immunotherapy; Other Treatment
4) By End User: Hospitals And Clinics; Academic Institutes
Subsegments:
1) By Uvea: Choroid Melanoma; Ciliary Body Melanoma; Iris Melanoma2) By Sclera: Scleral Melanoma
3) By Retina: Retinal Melanoma
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Eye Melanoma market report include:- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Amgen Inc.
- Koninklijke Philips N.V.
- Carl Zeiss AG
- Genentech Inc.
- Elekta Instrument AB
- Brainlab AG
- Optos Plc
- Castle Biosciences Inc.
- Heidelberg Engineering
- Nektar Therapeutics
- RaySearch Laboratories AB
- Nidek Co. Ltd
- IDEAYA Biosciences
- Immunocore Limited
- Topcon Healthcare
- Oraya Therapeutics Inc.
- Delcath Systems Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 9.89 Billion |
Forecasted Market Value ( USD | $ 13.77 Billion |
Compound Annual Growth Rate | 8.6% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |